Nội dung được dịch bởi AI, chỉ mang tính chất tham khảo
Chế tạo Microneedles Tan Đầu Ngón Cho Giao Thoa Thuốc Meloxicam Qua Da
Tóm tắt
Microneedles tan (MNs) cung cấp một phương pháp đơn giản, ít xâm lấn để đưa meloxicam (MX) vào da. Tuy nhiên, việc chế tạo MNs tan vẫn gặp phải một số thách thức như thời gian sản xuất dài, mất hoạt tính thuốc và khó khăn trong việc điều chỉnh lượng thuốc nạp vào MN. Để giải quyết những vấn đề này, chúng tôi đã phát triển microneedles tan đầu (TD MNs). Nhiều loại thuốc đã được bọc thành công, và lượng MX dao động từ 37,23 ± 8,40 đến 332,53 ± 13,37 μg được kiểm soát chính xác. Các ảnh hưởng của quy trình chế tạo đến tính ổn định của biomacromolecule đã được nghiên cứu và nhận thấy rằng tyrosinase giữ được 90,4% hoạt tính trong quá trình chế tạo. Toàn bộ quy trình chế tạo MN chỉ mất khoảng 1 giờ. Để đánh giá thêm tiềm năng của TD MNs, TD MNs MX đã được chuẩn bị cho các thí nghiệm giải phóng in vitro, thí nghiệm giải phóng in vivo, đánh giá độ an toàn, nghiên cứu dược động học và nghiên cứu dược lực học. Kết quả cho thấy TD MNs MX mang lại một số ưu điểm như giải phóng nhanh chóng thuốc được bọc (91,72% trong 30 phút), phân phối thuốc hiệu quả đến da (79,18%), không gây kích ứng da rõ rệt, khả năng sinh khả dụng tương đối tốt (122,3%) và có những tác động chống viêm và giảm đau mạnh mẽ. Dựa trên kết quả này, chúng tôi tin rằng TD MNs có tiềm năng hứa hẹn cho việc giao thoa thuốc MX qua da.
Từ khóa
#microneedles; meloxicam; chế tạo; giao thoa thuốc; giảm đau; chống viêmTài liệu tham khảo
Degner F, Sigmund R, Zeidler H. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin Ther. 2000;22(4):400–10. https://doi.org/10.1016/S0149-2918(00)89009-8.
Senna GE, Passalacqua G, Dama A, Crivellaro M, Schiappoli M, Bonadonna P, et al. Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs. Eur Ann Allergy Clin Immunol. 2003;35(10):393–6.
Pairet M, van Ryn J, Schierok H, Mauz A, Trummlitz G, Engelhardt G. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4′-isomer. Inflamm Res. 1998;47(6):270–6. https://doi.org/10.1007/s000110050329.
Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol. 1996;35(Suppl 1):68–77. https://doi.org/10.1093/rheumatology/35.suppl_1.68.
Lanes SF, Rodrigeuz LA, Hwangg E. Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin. Pharmacoepidemiology and drug safety. 2000;9(2):113–7. doi: https://doi.org/10.1002/(SICI)1099-1557(200003/04)9:2<113::AID-PDS478>3.0.CO;2–2.
Chen J, Gao Y. Strategies for meloxicam delivery to and across the skin: a review. Drug Delivery. 2016;23(8):3146–56. https://doi.org/10.3109/10717544.2016.1157839.
Altman RD, Barthel HR. Topical therapies for osteoarthritis. Drugs. 2011;71(10):1259–79. https://doi.org/10.2165/11592550-000000000-00000.
Wiechers JW. The barrier function of the skin in relation to percutaneous absorption of drugs. Pharmaceutisch weekblad Scientific edition. 1989;11(6):185–98. https://doi.org/10.1007/BF01959410.
YC A, Choi JK, Choi YK, Ki HM, Bae JHA. Novel transdermal patch incorporating meloxicam: in vitro and in vivo characterization. Int J Pharm. 2010;385(385):12–9.
Badran MM, Taha EI, Tayel MM, Al-Suwayeh SA. Ultra-fine self nanoemulsifying drug delivery system for transdermal delivery of meloxicam: dependency on the type of surfactants. J Mol Liq. 2014;190(190):16–22. https://doi.org/10.1016/j.molliq.2013.10.015.
Pathan I, Mangle M, Bairagi S. Design and characterization of nanoemulsion for transdermal delivery of meloxicam. Analytical. Chem Lett. 2016:286–95.
Sareen R, Kumar S, Gupta GD. Meloxicam carbopol-based gels: characterization and evaluation. Current Drug Delivery. 2011;8(4):407–15. https://doi.org/10.2174/156720111795768013.
Duangjit S, Obata Y, Sano H, Onuki Y, Opanasopit P, Ngawhirunpat T, et al. Comparative study of novel ultradeformable liposomes: menthosomes, transfersomes and liposomes for enhancing skin permeation of meloxicam. Biol Pharm Bull. 2014;37(2):239–47. https://doi.org/10.1248/bpb.b13-00576.
Fang JY, Sung KC, Wang JJ, Chu CC, Chen KT. The effects of iontophoresis and electroporation on transdermal delivery of buprenorphine from solutions and hydrogels. J Pharm Pharmacol. 2002;54(10):1329–37. https://doi.org/10.1211/002235702760345392.
Kim TY, Kim YI, Seo SK, Kim SH, Yang KH, Shin SC. Anti-Hyperalgesic effects of meloxicam hydrogel via phonophoresis in acute inflammation in rats; comparing systemic and topical application. Biomol Ther. 2009;17(3):305–10. https://doi.org/10.4062/biomolther.2009.17.3.305.
Garland MJ, Migalska K, Mahmood TMT, Singh TRR, Woolfson AD, Donnelly RF. Microneedle arrays as medical devices for enhanced transdermal drug delivery. Expert Rev Med Devices. 2011;8(4):459–82. https://doi.org/10.1586/erd.11.20.
Henry S, Mcallister DV, Allen MG, Prausnitz MR. Microfabricated microneedles: a novel approach to transdermal drug delivery. J Pharm Sci. 1998;87(8):922–5. https://doi.org/10.1021/js980042+.
Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery ☆. Adv Drug Deliv Rev. 2012;64(14):1547–68. https://doi.org/10.1016/j.addr.2012.04.005.
Donnelly RF, Garland MJ, Morrow DIJ, Migalska K, Singh TRR, Majithiya R, et al. Optical coherence tomography is a valuable tool in the study of the effects of microneedle geometry on skin penetration characteristics and in-skin dissolution. J Control Release. 2010;147(3):333–41. https://doi.org/10.1016/j.jconrel.2010.08.008.
Kaushik S, Hord AH, Denson DD, Mcallister DV, Smitra S, Allen MG, et al. Lack of pain associated with microfabricated microneedles. Anesth Analg. 2001;92(2):502–4. https://doi.org/10.1213/00000539-200102000-00041.
Witting M, Obst K, Pietzsch M, Friess W, Hedtrich S. Feasibility study for intraepidermal delivery of proteins using a solid microneedle array. Int J Pharm. 2015;486(1–2):52–8. https://doi.org/10.1016/j.ijpharm.2015.03.046.
Chen J, Qiu Y, Zhang S, Yang G, Gao Y. Controllable coating of microneedles for transdermal drug delivery. Drug Dev Ind Pharm. 2013;41(3):415–22. https://doi.org/10.3109/03639045.2013.873447.
Gill HS, Prausnitz MR. Coating formulations for microneedles. Pharm Res. 2007;24(7):1369–80. https://doi.org/10.1007/s11095-007-9286-4.
Khan H, Mehta P, Msallam H, Armitage D, Ahmad Z. Smart microneedle coatings for controlled delivery and biomedical analysis. J Drug Target. 2014;22(9):790–5. https://doi.org/10.3109/1061186X.2014.921926.
Chen JQY, Zhang S, Gao Y. Dissolving microneedle-based intradermal delivery of interferon-α-2b. Drug Dev Ind Pharm. 2016;42(6):890–6. https://doi.org/10.3109/03639045.2015.1096282.
Jun H, Han MR, Kang NG, Park JH, Park JH. Use of hollow microneedles for targeted delivery of phenylephrine to treat fecal incontinence. J Control Release. 2015;207:1–6. https://doi.org/10.1016/j.jconrel.2015.03.031.
Lutton REM, Larrañeta E, Kearney MC, Boyd P, Woolfson AD, Donnelly RFA. Novel scalable manufacturing process for the production of hydrogel-forming microneedle arrays. Int J Pharm. 2015;494(1):417–29. https://doi.org/10.1016/j.ijpharm.2015.08.049.
Ahmad Z, Stride E, Edirisinghe M. Novel preparation of transdermal drug-delivery patches and functional wound healing materials. J Drug Target. 2009;17(9):724–9. https://doi.org/10.3109/10611860903085386.
Amodwala S, Kumar P, Thakkar HP. Statistically optimized fast dissolving microneedle transdermal patch of meloxicam: a patient friendly approach to manage arthritis. Eur J Pharm Sci. 2017;104:114–23. https://doi.org/10.1016/j.ejps.2017.04.001.
Larrañeta E, Stewart S, Fallows SJ, Birkhäuer LL, Mccrudden MTC, Woolfson AD, et al. A facile system to evaluate in vitro drug release from dissolving microneedle arrays. Int J Pharm. 2016;497(1):62–9. https://doi.org/10.1016/j.ijpharm.2015.11.038.
Vijaya Kumar SG, Mishra DN. Preparation, characterization and in vitro dissolution studies of solid dispersion of meloxicam with PEG 6000. Yakugaku Zasshi. J Pharm Soc Japan. 2006;126(8):657–64. https://doi.org/10.1248/yakushi.126.657.
Chang J-S, P-C W, Huang Y-B, Tsai Y-H. In-vitro evaluation of meloxicam permeation using response surface methodology. J Food Drug Anal. 2006;14(3)
Momtaz S, Lall N, Basson A. Inhibitory activities of mushroom tyrosine and DOPA oxidation by plant extracts. S Afr J Bot. 2008;74(4):577–82. https://doi.org/10.1016/j.sajb.2008.02.005.
Winter CAREA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Exp Biol Med. 1962;111(3):544–7. https://doi.org/10.3181/00379727-111-27849.
Millan MJ. Serotonin and pain: evidence that activation of 5-HT 1A receptors does not elicit antinociception against noxious thermal, mechanical and chemical stimuli in mice. Pain. 1994;58(1):45–61. https://doi.org/10.1016/0304-3959(94)90184-8.
Kitchen I, Green PG. Differential effects of di-isopropylfluorophosphate poisoning and its treatment on opioid antinociception in the mouse. Life Sciences. 1983;33(Suppl 1):669–72.
Donnelly RF, Morrow DI, Singh TR, Migalska K, Mccarron PA, O’Mahony C, et al. Processing difficulties and instability of carbohydrate microneedle arrays. Drug Dev Ind Pharm. 2009;35(10):1242–54. https://doi.org/10.1080/03639040902882280.
Chu LY, Choi SO, Prausnitz MR. Fabrication of dissolving polymer microneedles for controlled drug encapsulation and delivery: bubble and pedestal microneedle designs. J Pharm Sci. 2010;99(10):4228–38. https://doi.org/10.1002/jps.22140.
Hong X, Wei L, Wu F, Wu Z, Chen L, Liu Z, et al. Dissolving and biodegradable microneedle technologies for transdermal sustained delivery of drug and vaccine. Drug Des Dev Therap. 2013;7(3):945–52.
Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(16):1613.
Cohn D, Salomon AH. Designing biodegradable multiblock PCL/PLA thermoplastic elastomers. Biomaterials. 2005;26(15):2297–305. https://doi.org/10.1016/j.biomaterials.2004.07.052.
Chu LY, Prausnitz MR. Separable arrowhead microneedles. J Controll Release Off J Controll Release Society. 2011;149(3):242–9.